CTNM (Contineum Therapeutics) Institutional Ownership: 85.13% (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTNM Contineum Therapeutics Inc CTNM
17 GF Score
Price $15.46
! 2 Warning Signs
View Full Analysis

What is Contineum Therapeutics Institutional Ownership?

Contineum Therapeutics CTNM -1.37% 17 Institutional Ownership is 85.13% as of Aug. 01, 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Contineum Therapeutics's institutional ownership is 85.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Contineum Therapeutics's Insider Ownership is 0.48%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Contineum Therapeutics's Float Percentage Of Total Shares Outstanding is 86.51%.

Contineum Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Contineum Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics Institutional Ownership Chart

Contineum Therapeutics Historical Data

The historical data trend for Contineum Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 15.62 15.67 15.67 20.32 20.43 20.64 21.34 14.90 15.04 21.72
CTNM
17GF Score
Contineum Therapeutics Inc CTNM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Contineum Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 85.13% mean?
Contineum Therapeutics (CTNM) has a Institutional Ownership of 85.13% as of Aug. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Contineum Therapeutics and its competitors.
Is Contineum Therapeutics' Institutional Ownership too high?
Contineum Therapeutics' current Institutional Ownership is 85.13%. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' Institutional Ownership compare to FDMT and PRME?
Contineum Therapeutics' Institutional Ownership of 85.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Contineum Therapeutics and its competitors. Contineum Therapeutics's current Institutional Ownership is 85.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current Institutional Ownership of 85.13%. The current Institutional Ownership is 85.13%. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current Institutional Ownership is 85.13% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Contineum Therapeutics Business Description

Address 3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score

Get the complete analysis for CTNM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.46
Price